Selective androgen receptor modulator has anti-tumor effects in ER-positive breast ca
A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.
More... |
All times are GMT -7. The time now is 07:39 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021